Critical role of STAT3 in IL-6–mediated drug resistance in human neuroblastoma

T Ara, R Nakata, MA Sheard, H Shimada, R Buettner… - Cancer research, 2013 - AACR
T Ara, R Nakata, MA Sheard, H Shimada, R Buettner, SG Groshen, L Ji, H Yu, R Jove…
Cancer research, 2013AACR
Drug resistance is a major cause of treatment failure in cancer. Here, we have evaluated the
role of STAT3 in environment-mediated drug resistance (EMDR) in human neuroblastoma.
We determined that STAT3 was not constitutively active in most neuroblastoma cell lines but
was rapidly activated upon treatment with interleukin (IL)-6 alone and in combination with
the soluble IL-6 receptor (sIL-6R). Treatment of neuroblastoma cells with IL-6 protected them
from drug-induced apoptosis in a STAT3-dependent manner because the protective effect of …
Abstract
Drug resistance is a major cause of treatment failure in cancer. Here, we have evaluated the role of STAT3 in environment-mediated drug resistance (EMDR) in human neuroblastoma. We determined that STAT3 was not constitutively active in most neuroblastoma cell lines but was rapidly activated upon treatment with interleukin (IL)-6 alone and in combination with the soluble IL-6 receptor (sIL-6R). Treatment of neuroblastoma cells with IL-6 protected them from drug-induced apoptosis in a STAT3-dependent manner because the protective effect of IL-6 was abrogated in the presence of a STAT3 inhibitor and upon STAT3 knockdown. STAT3 was necessary for the upregulation of several survival factors such as survivin (BIRC5) and Bcl-xL (BCL2L1) when cells were exposed to IL-6. Importantly, IL-6–mediated STAT3 activation was enhanced by sIL-6R produced by human monocytes, pointing to an important function of monocytes in promoting IL-6–mediated EMDR. Our data also point to the presence of reciprocal activation of STAT3 between tumor cells and bone marrow stromal cells including not only monocytes but also regulatory T cells (Treg) and nonmyeloid stromal cells. Thus, the data identify an IL-6/sIL-6R/STAT3 interactive pathway between neuroblastoma cells and their microenvironment that contributes to drug resistance. Cancer Res; 73(13); 3852–64. ©2013 AACR.
AACR